). This sex difference in susceptibility is due in part to the promotive effect of androgens secreted by the teste after puberty (Vesselinovitch et al., 1980; Moore et al., 1981; Kemp et al., 1989; Weghorst and Klaunig, 1989) . Furthermore, several studies (Vesselinovitch and Mihailovich, 1967; Vesselinovitch et al., 1980; Goldfarb and Pugh, 1990; Yamamoto et al., 1991; Tsutsui et al., 1992) have shown that ovariectomy after administation of carcinogens shortens the latent period in the development of hepatoceliular tumours and increases their incidence, indicating that the ovaries suppress hepatocellular tumorgeness These findinp suggt that an ovarian hormone, oestrogen or progesterone, suppresses hepatoceilular tumorigenesis in mice. Administration of 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB) to neonatal female mice induces hepatocellular tumorigenesis (Roe et al., 1971; Yamamoto et al., 1991) , and ovariectomy promotes developmnt of hepatocelular tumours (Yamamoto et al., 1991 tumours (Yamamoto et al., , 1993a Tsutsui et al., 1992) .
We have shown that the ovarian hormone oestradiol-17P (E2) suppresses hepatocellular tumorigenesis, but that the other ovarian hormone, progesterone, does not (Yamamoto et al., 1991 (Yamamoto et al., , 1993b . Moreover, we suggested that the suppressive action of E2 is due not to its direct action on the liver but to its indirect action on tissues other than the liver (Yamamoto et al., 1993b) . Since oestrogen increases secretion of prolactin by the pituitary gland (Chen et al., 1970; Meites, 1974) 1988; Davis and Linzer, 1989) , it is conceivable that prolactin is an extrahepatic mediator of oestrogen's suppression of hepatoceilular tumorigenesis. Therefore, to investigate the role of prolactin in hepatocellular tumorigenesis in mice, we emined hepatoclluar tumorigenesis induced by 3'-methyl-4-dimethylamninoazoben e in mice under various serum levels of prolatin. We produced high serm levels of prolactin by daily injections of perphenazine, a dopamine antagonist (Wicha et al., 1980; Shinha and Gilligan, 1982; Singtripop et al., 1991) , or trnsplantation of pituitary glands under the renal capsule (Chen et al., 1970; Lam et al., 1976) , and decreased the oestrogen-induced high serum levels of prolactin by daily injections of bromocripti, a dopamine agonist (Mori and Nagasawa, 1984; Wood et al., 1991 saline at a concentration of 1 mg ml ;0.1 ml of the solution was injected s.c. daily. Bromocriptine (2-bromo-a-ergocriptine methanesulphonate salt) was dissolved in 10% (v/v) ethanol in saline at a concentration of 1 mg ml'; 0.1 ml of the solution was injected s.c. daily. Bromocriptine was kindly supplied by Sandoz Pharmaceuticals (Tokyo, Japan).
Transplantation ofpituitary glands Four pituitary glands obtained from 5 to 6-month-old female C57BL/6 x DS-F1 mice that had received no treatments were transplanted under the kidney capsule of 6-month-old mice that had been treated with 3'-Me-DAB neonatally and undergone ovariectomy at 1 month of age.
Treatment of mice
The study consisted in two experiments (experiments I and II). All mice (318 mice) used in the experiments were treated neonatally with 3'-Me-DAB as described above, and underwent ovariectomy at I month of age. In experiment I ( Figure  1 ), the mice were divided into four groups (groups 1, 2, 3 and 4). Group 1 mice (n = 35) received daily injections of saline (0.1 ml) from the age of 6 months. Group 2 mice (n = 50) received daily injections of perphenazine (0.1 mg) dissolved in 0.1 ml of saline. Group 3 mice (n = 48) received transplants of four pituitary glands under the kidney capsule at 6 months of age. Group 4 mice (n = 53) received implants of E2 pellets (10 mg) at 1 month of age. In experiment II (Figure 2 ), the mice were divided into three groups (groups 1, 2 and 3). Group 1 mice (n = 54) received daily injections of 0.1 ml of vehicle (10% ethanol in saline) from the age of 6 months. Both groups 2 and 3 received implants of E2 pellets (10 mg) at 1 month of age. In addition, group 2 mice (n = 38) received daily injections of bromocriptine (0.1 mg) dissolved in 0.1 ml of vehicle, while group 3 mice (n = 40) received injections of vehicle (0.1 ml) only from the age of 6 months. At 12 months of age, blood was taken from the inferior vena cava of all mice under pentobarbital sodium anaesthesia, after which the mice were killed by cervical dislocation and their livers were promptly removed.
In experiment I. we examined the effects on hepatocellular tumorigenesis of high serum levels of prolactin, produced by either daily injections of perphenazine (Wicha et al., 1980; Shinha and Gilligan, 1982; Singtripop et al., 1991) Table I . The number of adenomatous nodules was not signintly affected by either implantation of E2 pellts or treatment with bromocriptine.
Serun prolatin kvels in mice that received E2 pellets were extrmely high, in agreement with data shown in Table I . Treatment with bromocriptine signifintly decreased serum prolactin to levels similar to those in mice treated with perphenazine or pituitary gland transplants, as shown in Table I . No carcnomas were found in any groups. No adenomatous nodules or carcinomas developed in the livers of 21 female mice at 12 months of age which had not been treated neonatally with 3'-Me-DAB, but had instead undergone ovariectomy at I month of age.
Incrases in serum levels of prolatin produced by injections of prhai (dopamine antagonist) and by pituitary grafts were accompanied by decreases in the incidence of adenomatous nodules. The greater the increase in serum klees of prolactin produced by mplantation of E2 pellets, the greater was the decrease in the incidence of nodules. Furthermore, bromocipne (dopamine agonist) decreased the high serum levels of prolactin induced by implantation of E2
pellets and increased the incidence of adenomatous nodules.
Dopamine agonists and antagonists produce changes in serum levels of prolactin (Shinha and Gilligan, 1982; Mon and Nagasawa, 1984; Singtripop et al., 1991; Wood et al., 1991) , but have also been reported to exert other effects. For example, it is reported that dopamine antagonists stimulate aldosterone and corticosterone secretion in rats (Goebel et al., 1992) and that bromocriptn increases serum levels of growth hormone in normal human subjects (Wood et al., 1991) . Pituitary grafts secrete growth hormone as well as prolactin (Blanck et al., 1984) . Moreover, a recent report by 
E2 pelets
The experimental design is shown in Figure 1 In rats prolactin has been shown to induce hepatic ornithine decarboxylase and plasminogen activator activity and specific enzyme markers expressed early in the GI phase of the cell cycle (Crowe et al., 1991) , to cause hypomethylation of DNA in the liver (Reddy and Reddy, -1990) , to stimulate DNA synthesis by hepatocytes (Buckley et al., 1986) and to produce hepatomegaly (Buckley et al., 1985) .
Furthermore, it is reported that prolactin promotes development of diethylnitrosamine-induced preneoplastic y-glutamyltranspeptidase-positive foci in the liver of female rats (Buckley et al., 1985) . Blank et al. (1987) reported that prolactin did not suppress growth in male rats of y-glutamyltransferase-positive hepatic foci induced by diethylnitrosamine followed by treatment with 2-acetylaminofluorene. Thus, the effects of prolactin on the development of carcinogen-induced hepatocellular tumours in rats may be opposite to those in mice, although it is unknown whether the effects of prolactin on normal hepatocytes differ in mice and rats.
The effects of oestrogens on hepatocellular tumorigenesis in rats are opposite to those in mice. In mice, a natural oestrogen, E2, and a synthetic oestrogen, ethinyloestradiol, have been reported to suppress carcinogen-induced hepatocellular tumorigenesis (Lee et al., 1989; Yamamoto et al., 1993a,b) . In contrast, in rats several synthetic oestrogens have been shown to promote carcinogen-induced hepatocellular tumorigenesis (Metzler and Degen, 1987; Campen et al., 1990; Mayol et al., 1992) . A synthetic oestrogen has been shown to increase serum levels of prolactin (Campen et al., 1990) . Synthetic oestrogens may exert toxic effects on the liver that contribute to the promotion of hepatocellular tumorigenesis (Metzler and Degen, 1987) . However, if the promotive effects of synthetic oestrogens on hepatocellular tumorigenesis are due to the high serum levels of prolactin which they produce, the difference in the effects of oestrogens on hepatocellular tumorigenesis in mice and rats might be due to the difference in the effects of prolactin on hepatocellular tumorigenesis.
In carcinogen-induced hepatocellular tumorigenesis in rats, the difference in the secretory pattern of growth hormone is due, at least in part, to the lesser susceptibility of females to carcinogens; higher basal levels of serum growth hormone in females suppresses hepatocellular tumorigenesis (Blank et al., 1987; Hallstrom et al., 1991) . The role of growth hormone in suppression of hepatocellular tumorigenesis in female mice is unknown, but the present results suggest that the pituitary gland plays a role in hepatocellular tumorigenesis in mice.
